UAB Leads a New Anti-Viral Drug Trial to Combat the Coronavirus
The University of Alabama at Birmingham is leading a new anti-viral drug trial in Wuhan, China to combat the coronavirus outbreak.
The World Health Organization declared the outbreak a “public health emergency of international concern” in late January. In a few weeks, the virus has killed over 1,000 people and infected more than 40,000 people worldwide.
The placebo-controlled trial will test the safety and effectiveness of the anti-viral drug remdesivir. It’s part of a study led by UAB to treat high-priority emerging infections such as the flu, Zika virus, dengue fever and 2019-nCoV, better known as the coronavirus. UAB is working with Gilead Sciences and nearly a dozen other universities across the U.S. as part of a five-year $37.5 million grant from the National Institute of Allergy and Infectious Diseases.
Dr. Richard Whitley is the lead researcher and distinguished professor of pediatrics at UAB. He says they’ve tested the drug on a few patients in the U.S., but the trial in Wuhan is the first time they’ll test it on large numbers of people.
“The drug has been released on what we call a compassionate plea basis for a few patients in the United States who were sick. And those patients all did well,” Whitley says. “But we don’t know whether it was the effect of the drug or the natural healing process that took place in those patients. So we need the data from this controlled study.”
Whitley says about 400 people in Wuhan will be part of the trial. He says the Federal Drug Administration authorized use of the drug in clinical trials after it was used to successfully treat MERS and SARS in animal models. MERS and SARS are viral respiratory illnesses caused by the coronavirus.
Whitley says as of right now researchers aren’t using mortality rate as a benchmark to determine whether remdesivir effectively treats the coronavirus. Instead, he says they’ll track whether it works based on the resolution of respiratory illness and the prevention of complications from a respiratory illness.
But Whitley warns that like the flu, the coronavirus can mutate.
“So what we have to be careful of is that we have backup drugs that can be used in case patients develop resistance to remdesivir,” Whitley says.
Whitley says they’ve been working with Southern Research to develop possible backup drugs they’ll begin testing on animal models. He says if those show promising results, they’ll work to get them developed as well.
Whitley says while scientists didn’t predict the magnitude of the coronavirus, he’s not surprised.
“What we need to be aware of is that the National Institutes of Health anticipated that we would see emerging infections occur in the United States and this is a classical example of it,” Whitley says. “Because of climate change we’ll see diseases like dengue. We’ve already seen West Nile virus in the United States. We’ve seen a few sporadic cases of Zika and we’ll certainly see chikungunya. So we’ve got to be prepared and that’s what we’re trying to do.”
Editor Note: UAB holds WBHM’s broadcast license but our news and business departments operate independently.
Senate panel to vote on federal judge nomination for Emil Bove, who defended Trump
The vote comes as scores of former DOJ lawyers and retired state and federal court judges say they fear his intense loyalty to the president would carry over onto the bench.
A ‘Crypto Week’ win: Congress passes 1st major crypto legislation in the U.S.
It was a remarkable win for the crypto industry — and for President Trump, who campaigned on making the country "the crypto capital of the planet."
How did Condé Nast go from dominance to decline? A new book explains
For decades, Condé Nast publications such as Vogue and Vanity Fair were consequential tastemakers. Writer Michael Grynbaum explores the heyday of these magazines and how they lost their footing.
1960s pop star Connie Francis has died. The singer’s life was touched by tragedies
1960s pop star Connie Francis has died. The first female singer to chart a number-one single on the Billboard Hot 100, she sold over 40 million records before the age of 25.
Marc Maron on why it’s time for his ‘WTF’ podcast to end
Marc Maron is proud of his run as host of his podcast, WTF. And because of that, he's bringing it to a close. He wants to avoid it becoming just another show "feeding the garbage bin of content."
Virginia is for … data centers? Residents are increasingly saying no
The world's highest concentration of data centers is in Virginia. Many residents are not happy about that.